We narrowed to 496 results for: bryan roth

#50465-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 31, 2019

Academic Institutions and Nonprofits only

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#50465-AAV11

Ready-to-use AAV11 particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#50477-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hM4D(Gi)-mCherry (#50477). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM4D(Gi)-mCherry plasmid DNA. CaMKIIa-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

March 12, 2021

Academic Institutions and Nonprofits only

#50469-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 27, 2024

Academic Institutions and Nonprofits only

#50469-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#50476-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 8, 2025

Academic Institutions and Nonprofits only

#75033-AAV9

Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#65417-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-dF-HA-KORD-IRES-mCitrine (#65417). In addition to the viral particles, you will also receive purified pAAV-hSyn-dF-HA-KORD-IRES-mCitrine plasmid DNA. hSyn-driven, Cre-dependent KORD expression with bicistronic mCitrine, for SALB-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Vardy et al Neuron. 2015 Apr 29. pii: S0896-6273(15)

Feb. 6, 2026

Academic Institutions and Nonprofits only

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#50467-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 10, 2019

Academic Institutions and Nonprofits only

#50458-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-DIO-rM3D(Gs)-mCherry (#50458). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-rM3D(Gs)-mCherry plasmid DNA. hSyn-driven, Cre-dependent rM3D(Gs) receptor with an mCherry reporter for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Nov. 13, 2025

Academic Institutions and Nonprofits only

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only